(NYSE: EBS) Emergent Biosolutions's forecast annual revenue growth rate of 1.82% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 278.9%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 58.25%.
Emergent Biosolutions's revenue in 2025 is $788,900,000.On average, 4 Wall Street analysts forecast EBS's revenue for 2025 to be $42,934,545,370, with the lowest EBS revenue forecast at $41,649,381,851, and the highest EBS revenue forecast at $44,646,170,997. On average, 3 Wall Street analysts forecast EBS's revenue for 2026 to be $49,464,877,694, with the lowest EBS revenue forecast at $36,543,390,951, and the highest EBS revenue forecast at $63,706,716,332.
In 2027, EBS is forecast to generate $35,646,349,966 in revenue, with the lowest revenue forecast at $34,587,547,492 and the highest revenue forecast at $37,058,086,598.